Altered Auditory Feedback (AAF) Devices for the Treatment of Stuttering (Speecheasy)
Governs coverage of altered auditory feedback devices for treatment of stuttering across Commercial, Medicare, and Community Care plans; summarizes clinical evidence and coding guidance.
For Commercial Plan Policy, the minimum age eligible for this treatment in criterion #1 was changed from 18 years to 7 years on 2/6/24.
For Commercial Policy, the minimum age eligible for this treatment in criterion #1 was changed from 7 years to 8 years on 1/6/25 to align with FDA approval.
For Commercial Plan Policy, modified certain requirements in section A to align with updated FDA-approved indications: 'Moderate-to-severe OSA with AHI: 15 to 100 events per hour [was previously 15 to 65 events per hour], and polysomnography within 24 months of Inspire stimulator consult; BMI < 40 kg/meter squared [was previously < 35 kg/meter squared].'
Modified criterion #A2 to allow polysomnography or home sleep testing within 24 months of Inspire stimulator consult.
Modified requirements in criterion A-5 and B-6 to define CPAP failure (AHI > 15 despite CPAP) or CPAP intolerance (<4 hours/night, 5 nights/week), or documentation supports non-compliance for at least 6 months.
Lowered age requirement from 22 to 18 years for general criteria and added coverage criteria for adolescents with Down Syndrome (ages 13 to 18).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.